BridgeMD
A study to assess the effects of zigakibart on IgA nephropathy.
EU CTIS ID: 2024-519699-24-00
What this study is testing
Does zigakibart treatment alter the course of disease in adults with IgAN?
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female adults 18 years of age or older who weigh at least 45 kg with a BMI no greater than 35.0 kg/m2 and were diagnosed with IgAN within the past 5 years.
- Moderate kidney function (eGFR ≥45 mL/min/1.73 m²).
- Persistent protein in urine defined as total urine protein ≥0.5 g/day or urine protein-creatinine ratio (UPCR) ≥0.5 g/g despite supportive therapy, or total urine protein >1.5 g/day or UPCR >1.5 g/g at the time of clinical presentation or diagnosis if diagnosed within the past 6 months.
You likely can't join if
- Does not have IgA vasculitis.
- Does not have a weakened immune system or unacceptably low immunoglobulin levels Total IgG (<6.0 g/L).
- Does not have urinary problems such as frequent urinary tract infections (UTIs) or trouble emptying the bladder.
- Does not have high blood pressure that is not well controlled.
- Has not used medications suppressing or affecting the immune system (not including short-term use of corticosteroids) in the past year.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- China
- Brazil
- Korea, Democratic People's Republic of
- Japan
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; China; Brazil; Korea, Democratic People's Republic of; Japan; Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.